By developing content that is specifically designed to appeal to the ideal customers, inbound marketing attracts better qualified prospects.
Incorrect use of medication has been associated with as many as 125,000 deaths per year in the U.S. alone.
Often a single CDMO can provide a comprehensive supply chain solution.
The most successful CDMOs have a tradition of innovation, cost-effective operational scale, and the ability to customize platforms to suit customer needs.
To maximize benefits of manufacturing parenterals, sponsors are tasking CDMOS with switching drug product from in-vial admixture to a premixed IV bag.
Demand for medicines is expanding as the global population continues to age and chronic diseases become increasingly widespread, even in emerging economies.
Equipment needs across the supply chain are changing, from initial discovery efforts to the packaging of final products.
Companies that have been able to successfully implement the customer experience approach have been found to be 4%-8% more profitable than their peers.
CLOs must employ state-of-the-art information, inventory and temperature control systems to provide patient-focused delivery of clinical trial materials.
Quality continues to be the ultimate decision driver for selection of a CRO according to the Nice Insight Survey.
2015 was a turning point for the U.S. biosimilar market: the FDA approved its first biosimilar drug, Zarxio, which was developed by Sandoz.
Among respondents to the 2016 Nice Insight CDMO survey, 75% expect their companies to increase expenditures on contract services over the next five years.
CDMOs today are seeing increased demand for drug substance development and GMP manufacturing services for innovator small-molecule drug development projects.
With the rising pace of mergers and acquisitions, companies are aiming to reduce costs through synergies and the consolidation of infrastructure and equipment.
The FDA has reviewed the use of continuous processes as a way to improve efficiency, and a handful of market leaders are taking the lead.